Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Clinical Trial ID NCT00667251

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.	J Clin Oncol	2015	1.36
3	Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.	Breast Cancer Res	2009	1.20
4	Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.	Int J Breast Cancer	2012	0.92
5	The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.	Curr Oncol	2009	0.83
6	Lapatinib for advanced or metastatic breast cancer.	Oncologist	2012	0.82
7	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.	Breast Cancer (Dove Med Press)	2012	0.79
8	Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.	Jpn J Clin Oncol	2010	0.79
9	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75